Stock ACCP ACCESS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights Access Pharmaceuticals, Inc. OTC Bulletin Board

Equities

ACCP

US00431M3088

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Access Pharmaceuticals, Inc.
05-30 Stifel Starts Abeona Therapeutics With Buy Rating, $21 Price Target MT
05-16 Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $21 From $36, Maintains Overweight Rating MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Abeona Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise
MT
Abeona Therapeutics Shares Slump After Plans to Reapply for Pz-cel Drug Approval
MT
Abeona Therapeutics Inc. Provides Regulatory Update on Pz-Cel
CI
Abeona Therapeutics Shares Fall After 2023 Results, FDA Observations on Cleveland Facility
MT
Abeona Therapeutics Shares Drop 13% After FDA Inspection of Cleveland Facility
DJ
Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Abeona Says FDA Confirms Target Action Date For Pz-cel Application After Inspection
MT
Abeona Therapeutics Inc. Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application
CI
Abeona Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Abeona Therapeutics Seeks FDA Priority Review for Potential Treatment of Recessive Dystrophic Epidermolysis Bullosa
MT
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
CI
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
CI
Abeona Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Abeona Therapeutics Submits Briefing Package for US FDA Meeting on Skin Disorder Investigational Therapy
MT
Abeona Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Abeona Therapeutics Announces Additional Phase 3 Viital Study Results for Eb-101 Presented At the International Societies for Investigative Dermatology 2023 Meeting
CI
Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Abeona Therapeutics Inc. Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL Study Results for Oral Presentation At International Societies for Investigative Dermatology 2023 Meeting
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABEO Stock
  4. ACCP Stock
  5. News Access Pharmaceuticals, Inc.
  6. Highlights